Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Das Thema chronische Unterbauch- und Viszeralschmerzen wird im Live-Webinar am 7. Mai von 17.30 bis 19 Uhr aus internistischer, gynäkologischer und psychologisch-neurowissenschaftlicher Perspektive beleuchtet. Besprochen werden krankheitsbedingte Ursachen, Mechanismen der kognitiven Schmerzmodulation sowie mögliche Therapieoptionen. Die Fortbildung ist mit 2 CME-Punkten zertifiziert. Melden Sie sich jetzt an!
Erweiterte Suche
Anmelden
nach oben
Clinical Reviews in Allergy & Immunology
Erschienen in: Clinical Reviews in Allergy & Immunology 1/2011

01.02.2011

Estrogen and Autoimmune Disease

verfasst von: Sara E. Walker

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Estrogenic hormones possess both immunostimulating and immunosuppressive properties. In systemic lupus erythematosus (SLE), pregnancy is associated with disease flares. In some situations, exogenous estrogen predisposes to development of new SLE, flares of preexisting SLE, and thromboses in susceptible individuals. In contrast, treatment with exogenous estrogen protects postmenopausal rheumatoid arthritis (RA) patients from active RA and osteoporosis. The search for estrogen-like compounds with anti-inflammatory properties may expand treatment options in RA.
Literatur
1.
Nalbandian G, Kovats S (2005) Estrogen, immunity & autoimmune disease. Curr Med Chem 5:85–91
2.
Cutolo M, Capellino S, Sulli A et al (2006) Estrogens and autoimmune disease. Ann NY Acad Sci 1089:538–547CrossRefPubMed
3.
4.
Cohen-Solal JFG, Jeganathan L, Kawabata D et al (2008) Hormonal regulation of B-cell function and systemic lupus erythematosus. Lupus 17:528–532CrossRefPubMed
5.
6.
Maul RW, Gearhart PJ (2009) Women, autoimmunity, and cancer: a dangerous liaison between estrogen and activation-induced deaminase? J Exp Med 206:11–13CrossRefPubMed
7.
Shim G-J, Kis LL, Warner M et al (2004) Autoimmune glomerulonephritis with spontaneous formation of splenic germinal centers in mice lacking the estrogen receptor alpha gene. Proc Natl Acad Sci U S A 101:1720–1724CrossRefPubMed
8.
Bynote KK, Hackenbert JM, Korach KS et al (2008) Estrogen receptor-alpha deficiency attenuates autoimmune disease in (NZB × NZW)Fl mice. Genes Immun 9:137–152CrossRefPubMed
9.
McCarty DJ, Manzi S, Medsger TA Jr et al (1995) Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum 38:1260–1270CrossRefPubMed
10.
Steinberg AD, Steinberg BJ (1985) Lupus disease activity associated with menstrual cycle. J Rheumatol 12:816–817PubMed
11.
Mok CC, Lau CS, Ho CT et al (1999) Do flares of systemic lupus erythematosus decline after menopause? Scand J Rheumatol 28:357–362CrossRefPubMed
12.
Mok CC, Wong RW, Lau CS et al (1999) Ovarian failure and flares of systemic lupus erythematosus. Arthritis Rheum 42:1274–1280CrossRefPubMed
13.
Costenbader KH, Feskanich D, Stampfer MJ et al (2007) Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum 56:1251–1262CrossRefPubMed
14.
Walker SE (2007) The importance of sex hormones in lupus. In: Wallace DJ, Hahn BH (eds) Dubois’ lupus erythematosus, 7th edn. Williams & Wilkins, Baltimore, pp 273–285
15.
Cooper GS, Dooley MA, Treadwell EL et al (2002) Hormonal and reproductive risk factors for development of systemic lupus erythematosus. Results of a population-based, case–control study. Arthritis Rheum 46:1830–1839CrossRefPubMed
16.
Ostensen M (1999) Sex hormones and pregnancy in rheumatoid arthritis and systemic lupus erythematosus. Ann NY Acad Sci 876:131–143CrossRefPubMed
17.
Doria A, Iaccarino L, Sarzi-Puttini P et al (2006) Estrogens in pregnancy and systemic lupus erythematosus. Ann NY Acad Sci 1069:247–256CrossRefPubMed
18.
Sanchez-Guerrero J, Karlson EW, Liang MH et al (1997) Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthrits Rheum 40:804–808CrossRef
19.
Bl S, Reidenberg MM, West S et al (1994) Shingles, allergies, family medical history, oral contraceptives, and other potential risk factors for systemic lupus erythematosus. Am J Epidemiol 140:632–642
20.
Petri M, Kim MY, Kalunian KC, Grossman J et al (2005) Combined oral contraceptives in women with systemic lupus erythematosus. New Engl J Med 353:2550–2558CrossRefPubMed
21.
Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L et al (2005) A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 353:2539–2549CrossRefPubMed
22.
US Preventive Services Task Force (2005) Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force. Ann Int Med 142:885–860
23.
Sanchez-Guerrero J, Liang MH, Karlson EW et al (1995) Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Int Med 122:430–433PubMed
24.
Barrett C, Neylon N, Snaith ML (1986) Oestrogen-induced systemic lupus erythematosus. Br J Rheumatol 25:300–301CrossRefPubMed
25.
Calvo-Alen FM, Bertoli AM, Bastian HM et al (2007) Systemic lupus erythematosus in a multiethnic US cohort (LUMINA L II): relationship between vascular events and the use of hormone replacement therapy in postmenopausal women. J Clin Rheumatol 13:261–265CrossRefPubMed
26.
Sanchez-Guerrero J, Gonzalez-Perez M, Durand-Darbajal M et al (2007) Menopause hormonal therapy in women with systemic lupus erythematosus. Arthritis Rheum 56:3070–3079CrossRefPubMed
27.
Buyon JP, Petri MA, Kim MY et al (2005) The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Int Med 142:953–962PubMed
28.
Grady D, Herrington D, Bittner V et al (2002) Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288:49–57CrossRefPubMed
29.
Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333CrossRefPubMed
30.
Huong DLT, Wechsler B, Piette J-C et al (1996) Risks of ovulation-induction therapy in systemic lupus erythematosus. Br J Rheumatol 35:1184–1186CrossRefPubMed
31.
Casoli P, Tumiati B, La Sala G (1997) Fatal exacerbation of systemic lupus erythematosus after induction of ovulation. J Rheumatol 24:1639–1640PubMed
32.
Guballa N, Sammaritano L, Schwartzman S et al (2000) Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum 43:550–556CrossRefPubMed
33.
Du LTH, Wechsler B, Piette J-C (2003) Induction d’ovulation et lupus. Ann Med Interne 154:45–50
34.
Silva CAA, Leal MM, Leone C et al (2002) Gonadal function in adolescents and young women with juvenile systemic lupus erythematosus. Lupus 11:419–425CrossRefPubMed
35.
Shabanova SS, Ananieva LP, Alekberova ZS, Guzov II (2008) Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin Exp Rheumatol 26:436–441PubMed
36.
Cutolo M, Lahita RG (2005) Estrogens and arthritis. Rheum Dis Clin N Am 31:19–27CrossRef
37.
Auborn KJ, Qi M, Yan XJ et al (2003) Lifespan is prolonged in autoimmune-prone (NZB/NZW) mice fed a diet supplemented with indole-3-carbinol. J Nutr 133:3610–3613PubMed
38.
Apelgren LD, Bailey DL, Fouts RS et al (1996) The effect of a selective estrogen receptor modulator on the progression of spontaneous autoimmune disease in MRLlpr/lpr mice. Cell Immunol 173:55–63CrossRefPubMed
39.
Sthoeger ZM, Zinger H, Mozes E (2002) Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of (NZB×NZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies. Ann Rheum Dis 62:341–346CrossRef
40.
Peeva E, Venkatesh J, Diamond B (2005) Tamoxifen blocks estrogen-induced B cell maturation but not survival. J Immunol 75:1415–1423
41.
Greenstein BD, Dhaher YY, de Bridges EF (1993) Effects of an aromatase inhibitor on thymus and kidney and on oestrogen receptors in female MRL/MP-lpr/lpr mice. Lupus 2(2):221–225CrossRefPubMed
42.
Rose E, Pillsbury DM (1944) Lupus erythematosus (erythematodes) and ovarian function: observations on a possible relationship, with report of six cases. Ann Int Med 21:1022–1034
43.
Laroche M, Borg S, Lassoued S, De Lafontan B et al (2007) Joint pain with aromatase inhibitors: abnormal frequency of Sjogren’s syndrome. J Rheumatol 34:2259–2263PubMed
44.
Cheong JL, Bucknall R (2009) Retinal vein thrombosis associated with a herbal phytoesrogen preparation in a susceptible patient. Postgrad Med J 81:266–267CrossRef
45.
Bhattoa HP, Bettembuk P, Balogh A et al (2004) The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic, postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Osteoporos Int 15:396–404CrossRefPubMed
46.
Sturgess AD, Evans DT, Mackay IR et al (1984) Effects of the oestrogen antagonist tamoxifen on disease indices in systemic lupus erythematosus. J Clin Lab Immunol 13:11–14PubMed
47.
Mok CC, To CH, Mak A et al (2005) Raloxifene for postmenopausal women with systemic lupus erythematosus. A pilot randomized controlled study. Arthritis Rheum 52:3997–4002CrossRefPubMed
48.
Rider V, Li X, Peterson G, Dawson J et al (2006) Differential expression of estrogen receptors in women with systemic lupus erythematosus. J Rheumatol 33:1093–1101PubMed
49.
Lee YJ, Shin KS, Kang SW et al (2004) Association of the oestrogen receptor alpha gene polymorphisms with disease onset in systemic lupus erythematosus. Ann Rheum Dis 63:1244–1249CrossRefPubMed
50.
Johansson M, Arlestig L, Moller B et al (2005) Oestrogen receptor alpha gene polymorphisms in systemic lupus erythematosus. Ann Rheum Dis 64:1611–1617CrossRefPubMed
51.
Abdou NI, Rider V, Greenwell C et al (2008) Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. Clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial. J Rheumatol 35:797–803PubMed
52.
Fairweather D, Frisancho-Kiss S, Rose NR (2008) Sex differences in autoimmune disease from a pathological perspective. Am J Pathol 173:600–609CrossRefPubMed
53.
Brahn E, Banquerigo MN, Lee JK et al (2008) An angiogenesis inhibitor, 2-methoxyestradiol, involutes rat collagen-induced arthritis and suppresses gene expression of synovial vascular endothelial growth factor and basic fibroblast growth factor. J Rheumatol 35:2119–2128CrossRefPubMed
54.
Shoenfeld Y, Zangman-Goddard G, Stojanovich L et al (2008) The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases. IMAJ 10:8–12PubMed
55.
Gerosa M, De Angelis V, Riboldi et al (2008) Rheumatoid arthritis: a female challenge. Women’s Health 4:195–201PubMed
56.
Sokka T, Toloza S, Cutolo M et al (2009) Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arth Res Ther 11:R7
57.
Straub RH, Harle P, Atzeni F et al (2005) Sex hormone concentrations in patients with rheumatoid arthritis are not normalized during 12 weeks of anti-tumor necrosis factor therapy. J Rheumatol 32:1253–1257PubMed
58.
Rovensky J, Kvetnansky R, Radikova Z et al (2005) Hormone concentrations in synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 23:292–296PubMed
59.
Capellino S, Montagna P, Villaggio B et al (2007) Hydroxylated estrogen metabolites influence the proliferation of cultured human monocytes: possible role in synovial tissue hyperplasia. Clin Exp Rheumatol 26:904–909
60.
Capellino S, Riepl B, Rauch L et al (2006) Quantitative determination of steroid hormone receptor positive cells in the synovium of patients with rheumatoid arthritis and osteoarthritis: is there a link to inflammation? Ann Rheum Dis 66:53–58CrossRefPubMed
61.
Spector TD, Hochberg MC (1989) The protective effect of the oral contraceptive pill on rheumatoid arthritis: an overview of the analytical epidemiological studies using meta-analysis. Br J Rheumatol 28(Suppl):11–12PubMed
62.
Hall GM, Daniels M, Huskisson EC et al (1994) A randomized controlled trial of the effect of hormone replacement therapy on disease activity in postmenopausal rheumatoid arthritis. Ann Rheum Dis 53:112–116CrossRefPubMed
63.
MacDonald AG, Murphy EA, Capell HA et al (1994) Effects of hormone replacement therapy in rheumatoid arthritis: a double blind placebo-controlled study. Ann Rheum Dis 53:54–57CrossRefPubMed
64.
Forsblad d’Elia H, Larsen A, Mattsson L et al (2003) Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. J Rheum 30:1456–1463
65.
Forsblad d’Elia H, Mattsson L, Ohlsson C et al (2003) Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor I. Arth Res Ther 5:R202–R209CrossRef
66.
Forsblad d’Elia H, Carlsten H (2008) The impact of hormone replacement therapy on humoral and cell-mediated immune responses in vivo in post-menopausal women with rheumatoid arthritis. Scand J Immunol 68:661–667CrossRefPubMed
67.
Maradit-Kremers H, Crowson CS, Nicola PJ et al (2005) Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 52:402–411CrossRefPubMed
68.
Jochems C, Lagerquist M, Hakansson C et al (2008) Long-term anti-arthritis and anti-osteopenic effects of raloxifene in established experimental postmenopausal polyarthritis. Clin Exp Immunol 152:593–597CrossRefPubMed
69.
Harnish DC (2006) Estrogen receptor ligands in the control of pathogenic inflammation. Internat Immunol 6:1413–1423CrossRef
70.
Carlsten H (2007) Interaction with estrogen receptors as treatment of arthritis and osteoporosis. In: Choi Y (ed) Osteoimmunology. Springer, New York, pp 83–92CrossRef
Metadaten
Titel
Estrogen and Autoimmune Disease
verfasst von
Sara E. Walker
Publikationsdatum
01.02.2011
Verlag
Humana Press Inc
Erschienen in
Clinical Reviews in Allergy & Immunology / Ausgabe 1/2011
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-010-8199-x

Weitere Artikel der Ausgabe 1/2011

Clinical Reviews in Allergy & Immunology 1/2011 Zur Ausgabe

OriginalPaper

Pregnancy Outcomes in Patients with Autoimmune Diseases and Anti-Ro/SSA Antibodies

OriginalPaper

Prolactin, Systemic Lupus Erythematosus, and Autoreactive B Cells: Lessons Learnt from Murine Models

OriginalPaper

The Unexplained Female Predominance of Systemic Lupus Erythematosus: Clues from Genetic and Cytokine Studies

ReviewPaper

Estrogen Receptors in Immunity and Autoimmunity

OriginalPaper

Prolactin and Autoimmunity

BriefCommunication

Reproductive Immunology: a Focus on the Role of Female Sex Hormones and Other Gender-Related Factors

Neu im Fachgebiet HNO

Nur selten Nachblutungen nach Abszesstonsillektomie

03.05.2024 Tonsillektomie Nachrichten

In einer Metaanalyse von 18 Studien war die Rate von Nachblutungen nach einer Abszesstonsillektomie mit weniger als 7% recht niedrig. Nur rund 2% der Behandelten mussten nachoperiert werden. Die Therapie scheint damit recht sicher zu sein.

Rezidivierender Peritonsillarabszess nach Oralsex

02.05.2024 Peritonsillarabszess Kasuistik

Die erotischen Dimensionen von Peritonsillarabszessen scheinen eng begrenzt zu sein. Das heißt aber nicht, solche Abszesse und Erotik hätten nichts miteinander gemein, wie ein Fallbericht verdeutlicht.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

30.04.2024 Rhinitis und Sinusitis Nachrichten

Persistieren Sinusitisbeschwerden bei Kindern länger als zehn Tage, ist eine Antibiotikatherapie häufig gut wirksam: Ein Therapieversagen ist damit zu über 40% seltener zu beobachten als unter Placebo.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise